The initial target will be the top 15 centers but it is worth knowing that Mesoblast and remestemcel-L have had a footprint in about 43 unique medical institutions in the US over the past 10 years.
From the Expanded Access Program that dates from Osiris days and started in 2008, expand on the linked page to show the 27 study locations.
From the P3 trial there were another 32, with a crossover to around 43 places.
The results over all that time with both EAP and P3 trial were rather consistent, and are being leveraged in at least a couple of ways for BLA. I also suspect that at least the Pediatric BMT world in the US will be relatively close knit, in as much that news will travel reasonably quickly.
The initial target will be the top 15 centers but it is worth...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.065(4.66%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.41 | $1.50 | $1.40 | $5.699M | 3.943M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 122380 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 11015 | 2 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |